Investors

PPI is presently raising a Series A round of funding in the amount of $7MM  which will enable the company to take  PP1-1501 through human proof of concept and PPI-1401, PPI-1601 and PPI-1602 through all pre-clinical  studies.

For those interested in receiving a non-confidential presentation you may contact PPI at: info@polymericparticles.com